Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) - Analysts at HC Wainwright dropped their Q1 2025 earnings per share estimates for shares of Roivant Sciences in a research note issued to...
Roivant Sciences (NASDAQ:ROIV - Free Report) had its target price increased by HC Wainwright from $17.00 to $18.00 in a research report report published on Wednesday morning, Benzinga reports. The...
Roivant's board of directors has approved a share repurchase program for up to $1.5 billion of the company's common shares, including an agreed repurchase of the entire Sumitomo Pharma stake for $648...
Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) saw unusually large options trading on Tuesday. Stock investors purchased 11,070 call options on the company. This represents an increase of...
Roivant Sciences and Priovant Therapeutics report Phase 2 results for brepocitinib in treating non-anterior non-infectious uveitis. Week 24 data show promising efficacy, with lower treatment failure...
In trading on Tuesday, shares of Roivant Sciences Ltd (ROIV) crossed above their 200 day moving average of 10.55, changing hands as high as 11.26 per share. Roivant Sciences Ltd shares are...
Shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) gapped up prior to trading on Tuesday . The stock had previously closed at $10.43, but opened at $10.93. Roivant Sciences shares last...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) traded down 4% on Thursday . The stock traded as low as $10.37 and last traded at $10.41. 3,304,999 shares traded hands during mid-day...